Overview

• Full 72‑week results presented at EASD and published in NEJM show average weight loss of 11.2% at the 36 mg dose in 3,127 adults with obesity, with 18.4% losing at least 20% and a plateau emerging for many patients.
• Benefits extended to cardiometabolic markers, including lower blood pressure, improved lipids and smaller waistlines, while side effects were mainly gastrointestinal with 10.3% discontinuation at the top dose, five mild pancreatitis cases and modest pulse increases.
• A 1,698‑patient head‑to‑head trial in type 2 diabetes found orforglipron cut A1C by up to 2.2% and weight by 9.2%, exceeding oral semaglutide’s 1.4% A1C reduction and 5.3% weight loss at its 14 mg dose.
• Lilly says it will file for approval this year, and Wall Street research notes orforglipron could be a candidate for the FDA’s new “Commissioner’s National Priority Voucher” pilot that targets one‑ to two‑month reviews.
• Clinicians in London report a postcode lottery for injectable GLP‑1 access and recent police seizures of suspected counterfeit products, reinforcing expectations that an oral option could expand supervised, affordable treatment.